{
  "title": "Regulatory Compliance Report",
  "protocol_id": "LMN-0801-001",
  "indication": "Obesity",
  "sponsor": "Lumen Biosciences",
  "version": "1.1c",
  "date": "2025-03-07",
  "overall_compliance_score": 94,
  "compliance_status": "Ready for submission",
  "agency_alignment": {
    "FDA": 95,
    "EMA": 92,
    "PMDA": 89,
    "Health Canada": 94,
    "TGA": 91
  },
  "section_scores": [
    {
      "section": "Study Design",
      "score": 96,
      "status": "Compliant",
      "comments": "Design consistent with regulatory expectations for obesity trials"
    },
    {
      "section": "Endpoint Selection",
      "score": 92,
      "status": "Compliant",
      "comments": "Primary and secondary endpoints align with FDA guidance"
    },
    {
      "section": "Statistical Analysis",
      "score": 95,
      "status": "Compliant",
      "comments": "Analysis plan meets ICH E9 requirements"
    },
    {
      "section": "Safety Monitoring",
      "score": 98,
      "status": "Compliant",
      "comments": "Comprehensive safety monitoring and reporting plan"
    },
    {
      "section": "Inclusion/Exclusion Criteria",
      "score": 94,
      "status": "Compliant",
      "comments": "Criteria align with regulatory expectations for target population"
    },
    {
      "section": "Informed Consent",
      "score": 90,
      "status": "Minor findings",
      "comments": "Minor clarifications needed on risks section"
    },
    {
      "section": "Data Management",
      "score": 93,
      "status": "Compliant",
      "comments": "Data integrity controls meet 21 CFR Part 11 requirements"
    }
  ],
  "findings": [
    {
      "severity": "Low",
      "section": "Informed Consent",
      "finding": "Additional detail needed on potential risks of microalgae-produced biologics",
      "recommendation": "Expand section 4.2 of ICF with specific risk language"
    },
    {
      "severity": "Low",
      "section": "Statistical Analysis",
      "finding": "Missing detail on handling of specific subgroup analyses",
      "recommendation": "Add prespecified subgroup analysis methodology to SAP"
    },
    {
      "severity": "Low",
      "section": "Study Procedures",
      "finding": "Visit window flexibility could be better defined",
      "recommendation": "Specify acceptable visit windows more explicitly"
    }
  ],
  "regulatory_guidance_applied": [
    "FDA Guidance for Industry: Developing Products for Weight Management (2007)",
    "EMA Guideline on Clinical Evaluation of Medicinal Products used in Weight Control (2016)",
    "ICH E9 Statistical Principles for Clinical Trials",
    "ICH E6(R2) Good Clinical Practice",
    "FDA Guidance on Patient-Reported Outcome Measures (2009)"
  ],
  "verification_history": [
    {
      "date": "2025-02-15",
      "score": 86,
      "verifier": "Regulatory Compliance System"
    },
    {
      "date": "2025-03-01",
      "score": 91,
      "verifier": "Regulatory Compliance System"
    },
    {
      "date": "2025-03-07",
      "score": 94,
      "verifier": "Regulatory Compliance System"
    }
  ]
}